Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor

Breast Cancer

Volumn 17, Issue 4, 2010, Pages 254-260

  Yamamoto, Yutaka ^a   Masuda, Norikazu ^b   Ohtake, Tohru ^c   Yamashita, Hiroko ^d   Saji, Shigehira ^e   Kimijima, Izo ^c   Kasahara, Yoshio ^f   Ishikawa, Takashi ^g   Sawaki, Masataka ^h   Hozumi, Yasuo ⁱ   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f FUKUI KEN SAISEIKAI HOSPITAL   (Japan)

^g YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^h NAGOYA UNIVERSITY HOSPITAL   (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Anastrozole; Letrozole; Resistance to aromatase inhibitor; Toremifene

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FADROZOLE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ANAMNESIS; ANOREXIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RELAPSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; HAIR LOSS; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; NIGHT SWEAT; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POSTMENOPAUSE; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TOREMIFENE; TREATMENT OUTCOME;

EID: 77958100854     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0148-2     Document Type: Article

References (22)

1. H Iwase 2008 Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer Breast Cancer 15 4 278 290 10.1007/s12282-008-0071-y 18810576
2. GN Hortobagyi 2002 Novel approaches to the management of bone metastases in patients with breast cancer Semin Oncol 29 134 144 1:CAS:528: DC%2BD38XmsFWntL8%3D 12138408
3. LE Stenbygaard J Herrstedt JF Thomsen KR Svendsen SA Engelholm P Dombernowsky 1993 Toremifene and tamoxifen in advanced breast cancer-a double-blind cross-over trial Breast Cancer Res Treat 25 57 63 1:STN:280:DyaK3s3pvV2gtQ%3D%3D 10.1007/BF00662401 8518408
4. S Pyrhonen J Ellmen J Vuorinen M Gershanovich T Tominaga M Kaufmann, et al. 1999 Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer Breast Cancer Res Treat 56 133 143 1:CAS:528:DyaK1MXnvVKitr4%3D 10.1023/A:1006250213357 10573106
5. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
6. TJ Whelan KI Pritchard 2006 Managing patients on endocrine therapy: focus on quality-of-life issues Clin Cancer Res 12 1056s 1060s 1:CAS:528: DC%2BD28XhtFeitLk%3D 10.1158/1078-0432.CCR-05-2185 16467124 (Pubitemid 43259843)
7. Y Yamamoto H Iwase 2008 Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer Int J Clin Oncol 13 384 394 1:CAS:528:DC%2BD1cXht1Oktr3O 10.1007/s10147-008- 0828-5 18946748
8. SJ Howell SR Johnston A Howell 2004 The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer Best Pract Res Clin Endocrinol Metab 18 47 66 1:CAS:528: DC%2BD3sXpvVWmurk%3D 10.1016/j.beem.2003.08.002 14687597 (Pubitemid 38324626)
9. RW Carlson IC Henderson 2003 Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole Breast Cancer Res Treat 80 Suppl 1 S19 S26 1:CAS:528:DC%2BD3sXosVait7c%3D 10.1023/A:1025459232293 14535531 discussion S27-18
10. CL Vogel I Shemano J Schoenfelder RA Gams MR Green 1993 Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer J Clin Oncol 11 345 350 1:STN:280:DyaK3s7kslyluw%3D%3D 8426212
11. K Asaishi T Tominaga O Abe M Izuo Y Nomura 1993 Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer Gan To Kagaku Ryoho 20 91 99 1:STN:280:DyaK3s7jsFGkuw%3D%3D 8422190
12. PE Jonsson M Malmberg L Bergljung C Ingvar M Ericsson S Ryden, et al. 1991 Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment Anticancer Res 11 873 875 1:STN:280:DyaK3M3ptVOlug%3D%3D 1829600
13. HD Homesley I Shemano RA Gams DS Harry PG Hickox RW Rebar, et al. 1993 Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women Am J Clin Oncol 16 117 122 1:STN:280:DyaK3s7pvVygtg%3D%3D 10.1097/00000421-199304000- 00007 8452102
14. D Dodwell G Coombes JM Bliss LS Kilburn S Johnston 2008 Combining fulvestrant (Faslodextrade mark) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial Clin Oncol (R Coll Radiol) 20 5 321 324 1:STN:280:DC%2BD1cznsFWjtQ%3D%3D
15. J Geisler 2008 Aromatase inhibitors: from bench to bedside and back Breast Cancer 15 17 26 10.1007/s12282-007-0002-3 18224389
16. B Thurlimann JF Robertson JM Nabholtz A Buzdar J Bonneterre 2003 Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women Eur J Cancer 39 2310 2317 1:CAS:528:DC%2BD3sXnvVymtbs%3D 10.1016/S0959-8049(03)00602-6 14556922 (Pubitemid 37214855)
17. PE Lonning E Bajetta R Murray M Tubiana-Hulin PD Eisenberg E Mickiewicz, et al. 2000 Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial J Clin Oncol 18 2234 2244 1:CAS:528:DC%2BD3cXktlagsbw%3D 10829043
18. Bertelli G, Garrone O, Merlano M. Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Proc Am Soc Clin Oncol. 2002; 21:abstr 238.
19. Y Iino Y Takai T Ando N Sugamata M Maemura T Takeo, et al. 1993 Effect of toremifene on the growth, hormone receptors and insulin-like growth factor-1 of hormone-dependent MCF-7 tumors in athymic mice Cancer Chemother Pharmacol 32 353 358 1:CAS:528:DyaK2cXis1Sks7w%3D 10.1007/BF00735918 8339385
20. M Okada A Ogasawara K Sekine C Seno K Nishikawa 2001 Antiangiogenic and antimetastatic effects of toremifene citrate Gan To Kagaku Ryoho 28 1099 1104 1:CAS:528:DC%2BD3MXmvVCisLs%3D 11525025
21. JK Ruohola EM Valve MJ Karkkainen V Joukov K Alitalo PL Harkonen 1999 Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells Mol Cell Endocrinol 149 29 40 1:CAS:528:DyaK1MXisFCrs7k%3D 10.1016/S0303-7207(99)00003-9 10375015 (Pubitemid 29236221)
22. Y Yamamoto T Kawazoe H Iwase 2005 Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer Gan To Kagaku Ryoho 32 1415 1419 16227740